Annons

Swedish Bactiguard to enter into an exclusive distribution agreement with Cadila Pharmaceuticals

Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India. A signing process will take place at the Swedish Ambassador’s residency tonight. Cadila Pharmaceuticals will sell the entire line of Bactiguard´s products throughout India.

Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India. A signing process will take place at the Swedish Ambassador’s residency tonight.

Cadila Pharmaceuticals will sell the entire line of Bactiguard´s products throughout India. The Indian medical device market is currently worth approximately 2 billion US dollar and growing 15% annually.

“For Bactiguard this is a milestone. India is one of the world’s most interesting and fastest growing markets right now, and we are proud to be able to help India with our expertise in the field of infection protection. We are hoping to reduce the number of hospital acquired infections and thereby also reduce the use of antibiotics in India together with Cadila. I am very proud to be able to work with Cadila to improve health care in India”, says Christian Kinch, CEO of Bactiguard.

Indravadan A Modi, Chairman, Cadila Pharmaceuticals Ltd. has explained why Cadila has chosen to work with Bactiguard. “We have chosen to work with Bactiguard of Sweden because hospital- acquired infections are a big problem for patients in our country and Bactiguard has a unique solution targeted at preventing health care associated infections. We are confident that hospitals in our country will embrace Bactiguard’s clinically proven solution in order to help save lives in India”.

This co-operation between Cadila Pharmaceuticals and Bactiguard was facilitated by Dr.C.B. Sanjeevi of Karolinska Institute and Invest Sweden assisted together. Another important role was played by the Swedish EKN, Export Credit Guarantee Authority to make the exclusive agreement.

Photo text: Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals Ltd together with Mr Christian Kinch, CEO, Bactiguard

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over 90 other countries across the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.


Pressmeddelandet skickades med Mynewsdesk

Bactiguard provides world-leading solutions preventing hospital-acquired infections - the 4th largest cause of death in the western world. By using Bactiguard technology Governments can reduce healthcare cost, lower the use of antibiotics and save lives. The Bactiguard technology consists of an extremely thin noble metal coating, with antimicrobial and biocompatible properties that can be used on all sorts of medical devices. The Bactiguard coated urinary catheter has since 1995 been used by more than 110 million patients in the US. Today Bactiguard offers a full range portfolio within infection prevention in the urinary tract, respiratory tract and blood stream.


Vi använder cookies för att förbättra funktionaliteten på våra sajter, för att kunna rikta relevant innehåll och annonser till dig och för att vi ska kunna säkerställa att tjänsterna fungerar som de ska. Läs mer i vår cookiepolicy.
Läs mer

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?